58 articles, transcripts, and reports
Biogen Inc. (NASDAQ: BIIB) reported second quarter 2022 earnings results today. Total revenue decreased 7% year-over-year to $2.58 billion. Net income attributable to Biogen Inc.…
Biogen Inc. (NASDAQ: BIIB) is currently going through a difficult phase as the biotechnology firm’s main products face stiff competition and the ambitious launch of…
Biogen Inc. (NASDAQ: BIIB) reported first quarter 2022 earnings results today. Total revenue decreased 6% year-over-year to $2.53 billion. GAAP net income attributable to Biogen Inc.…
Biogen Inc (NASDAQ: BIIB) Q4 2021 Earnings Conference
Biogen, Inc. (NASDAQ: BIIB) Q4 2021 earnings call dated Feb. 03, 2022 Corporate Participants: Michael Hencke — Head of Investor Relations Michel Vounatsos — Chief Executive Officer Priya Singhal — Head…
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB)…
Biogen Inc (NASDAQ: BIIB) Q3 2021 Earnings Conference
Biogen, Inc. (NASDAQ: BIIB) Q3 2021 earnings call dated Oct. 20, 2021 Corporate Participants: Michael Hencke — Investor Relations Michel Vounatsos — Chief Executive Officer Alfred Sandrock — Head of Research…
Biogen Inc. (NASDAQ: BIIB) Q2 2021 earnings call dated Jul. 22, 2021 Corporate Participants: Mike Hencke — Director of Investor Relations Michel Vounatsos — Chief Executive Officer Alfred Sandrock — Head…
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Thursday said its second-quarter earnings and revenues decreased from last year. The results, however, came in above analysts’ forecast.…
